(2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-amine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-amine
• 化学式: C₂₀H₃₁N
• 分子量: 285.5
• InChiKey: ILYSIVSSNXQZQG-MKOSUFFBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Retinol binding protein and transthyretin modulators for treating diabetes
  申请人：Sirion Therapeutics, Inc.

  公开号：EP1930046A1

  公开（公告）日：2008-06-11

  Described herein are methods and compositions for treating certain retionol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.

  本文描述了通过调节受试者体内转甲状腺素（TTR）和视黄醇结合蛋白（RBP）的可用性来治疗某些视黄醇相关疾病和病症的方法和组合物。例如，这些方法和组合物提供了治疗和/或预防老年性黄斑变性和/或营养不良、代谢紊乱、特发性颅内高压、骨质疏松症以及蛋白质错误折叠和聚集疾病的治疗剂。所公开的组合物可用作单剂疗法，也可与其他制剂或疗法联合使用。此外，本文还描述了用于选择可调节受试者体内 TTR 和 RBP 可用性的适当制剂的方法和检测方法。
• Retinyl derivatives for treating ophtalmic conditions
  申请人：Sirion Therapeutics, Inc.

  公开号：EP2025336A1

  公开（公告）日：2009-02-18

  Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions. Such compounds and their derivatives may be used as single agent therapy or in combination with other agents or therapies.

  导致可逆性夜盲症的化合物可用于治疗与视觉周期过程中积累的废物过度产生有关的眼科疾病。我们描述了使用此类化合物及其衍生物治疗黄斑变性和营养不良等眼科疾病或缓解与此类眼科疾病相关的症状的方法和组合物。此类化合物及其衍生物可用作单药治疗，也可与其他药物或疗法联合使用。
• Retinol binding protein and transthyretin modulators for treating hypertosis, Alzheimer's disease or idiopathic intracranial hypertension
  申请人：ReVision Therapeutics, Inc.

  公开号：EP2289500A1

  公开（公告）日：2011-03-02

  Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.

  本文描述了通过调节受试者体内转甲状腺素（TTR）和视黄醇结合蛋白（RBP）的可用性来治疗某些视黄醇相关疾病和病症的方法和组合物。例如，这些方法和组合物提供了治疗和/或预防老年性黄斑变性和/或营养不良、代谢紊乱、特发性颅内高压、骨质疏松症以及蛋白质错误折叠和聚集疾病的治疗剂。所公开的组合物可用作单剂疗法，也可与其他制剂或疗法联合使用。此外，本文还描述了用于选择可调节受试者体内 TTR 和 RBP 可用性的适当制剂的方法和检测方法。
• Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation
  申请人：Mata L. Nathan

  公开号：US20060094063A1

  公开（公告）日：2006-05-04

  Described herein are methods and compositions for the detection of transthyretin (TTR), retinol binding protein (RBP) and retinol complex formation. The methods and compositions described herein also provide for the screening of modulators of retinol-RBP-TTR complex formation. Furthermore, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies.

  本文描述的是检测转甲状腺素（TTR）、视黄醇结合蛋白（RBP）和视黄醇复合物形成的方法和组合物。本文所述的方法和组合物还可用于筛选视黄醇-RBP-TTR 复合物形成的调节剂。此外，这些方法和组合物还提供了治疗和/或预防老年性黄斑变性和/或营养不良的治疗剂。
• Detection and analysis of ophthalmically-relevant fluorescent molecules
  申请人：Mata L. Nathan

  公开号：US20060099714A1

  公开（公告）日：2006-05-11

  Disclosed herein are methods and devices for detecting fluorescent molecules that are relevant to the health of the eye and related tissues. The presence of such molecules in the eye and related tissues can be used to diagnose whether the patient has certain diseases, including the macular degenerations and macular dystrophies. The amount of such molecules in the eye and related tissues can be used to determine the extent and stage of these diseases, to monitor the progress of these diseases, to design treatment strategies, to monitor the effectiveness of such treatments and to develop new therapies.

  本文公开了检测与眼睛及相关组织健康有关的荧光分子的方法和装置。这些分子在眼睛和相关组织中的存在可用来诊断病人是否患有某些疾病，包括黄斑变性和黄斑营养不良。眼睛和相关组织中此类分子的含量可用于确定这些疾病的程度和阶段、监测这些疾病的进展情况、设计治疗策略、监测这些治疗的效果以及开发新的疗法。